Lab
My Lab
My Lab was paid $1.31M by Medicaid between Feb 2022 and May 2023, across 11 billing codes. Its largest line is 0241U, Neonatal screening for hereditary disorders, genomic sequence analysis panel — 31% of everything it billed.
33Billing provider infoMY LAB
LEXINGTON, SC 29072
LEXINGTON, SC 29072
33aNPI1184359143assigned 07/22/2022
33bProvider typeClinical Medical Laboratory
28Total paid$1.31M
24GClaims24,196
24DCodes billed11
24AFirst – last monthFeb 2022 – May 2023
Compared with peers
Next to other Clinical Medical Laboratory providers in South Carolina
Rank by total paid#10 of 39
Median peer was paid$403K
This provider vs. median3.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2022 | 18,297 | $931K | |
| 2023 | 5,899 | $381K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 31% | 3,373 | 2,857 | $406K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 20% | 2,173 | 1,736 | $267K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | 17% | 6,196 | 4,967 | $217K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 11% | 1,004 | 830 | $140K |
| G2024 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source | 8.2% | 5,156 | 4,265 | $107K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 6.0% | 993 | 876 | $79K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 4.2% | 2,700 | 2,080 | $55K |
| 87428 | 2.0% | 607 | 553 | $26K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1.2% | 1,780 | 1,436 | $15K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 14 | 14 | $556.70 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 200 | 181 | $25.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMANNING, JAMES (OWNER)
| Provider | Location | Paid |
|---|---|---|
| City of Auburn Hills | Auburn Hills, MI | $873K |
| M Holdings LLC | Lexington, SC | $355K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.